Don M Bailey
CIK 1223697 · See Remarks · last filed 2024-07-03
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Charts
Trading activity, where the exposure sits, and each trade against the stock price.
QCOR price and trades
Daily close with each Form 4 filing on this company marked: green = open-market buy, red = open-market sale, purple = grants, exercises, gifts and other non-market transactions. Marker size scales with the dollar value.
Shares held
Shares owned after each reported transaction on this company (direct holdings as reported).
Open-market buying and selling
by monthDollar value of open-market purchases (code P, up) and sales (code S, down) across all companies, by filing month. Grants, exercises and gifts are excluded.
Exposure by company
latestMost recently reported shares × current price. Faded bars (*) have had no filing in 3 years, so the person may no longer hold them. Click a bar to chart that company.
Filer Profile
SUITE D
ANAHEIM, CA 92607
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| LCTX | Director | 158,801 | $1.00 | $158.3K | $100.0K | 6 | 2024-07-03 |
| Asterias Biotherapeutics, Inc. (AST) Delisted | Director | 88,235 | — | — | $0 | 2 | 2018-06-25 |
| Insight Molecular Diagnostics Inc. (OCX) Delisted | Director | 12,350 | $3.20 | $39.5K | $0 | 3 | 2017-06-19 |
| Asterias Biotherapeutics, Inc. (AST.WS) Delisted | Director | 88,235 | — | — | $299.1K | 2 | 2017-04-03 |
| Keenova Therapeutics plc (MNK) Delisted | Director | 227,952 | $0.34 | $77.5K | -$39.07M | 10 | 2016-03-18 |
| QUESTCOR PHARMACEUTICALS INC (QCOR) Delisted | See Remarks | 239,437 | — | — | -$57.24M | 43 | 2014-08-15 |
| STAA | Director | 123,937 | $23.23 | $2.88M | $303.9K | 13 | 2013-05-16 |
| QUESTCOR PHARMACEUTICALS INC (QSC) Delisted | PRESIDENT & CEO | 0 | — | — | $0 | 5 | 2008-02-19 |
| COMARCO INC (CMRO) Delisted | Chairman of the Board | 66,095 | — | — | $0 | 2 | 2007-06-12 |
Recent Filings · Page 2 of 9
90 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2017-06-19 | Insight Molecular Diagnostics Inc. (OCX) Delisted | Grant (A) | — | $0 | EDGAR |
| 2017-04-03 | Asterias Biotherapeutics, Inc. (AST.WS) Delisted | Grant (A) | — | $0 | EDGAR |
| 2016-10-19 | Insight Molecular Diagnostics Inc. (OCX) Delisted | Grant (A) | — | $0 | EDGAR |
| 2016-08-30 | Insight Molecular Diagnostics Inc. (OCX) Delisted | Grant (A) | — | $0 | EDGAR |
| 2016-05-17 | Asterias Biotherapeutics, Inc. (AST.WS) Delisted | Buy (P) | +88,235 | $299.1K | EDGAR |
| 2016-03-18 | Keenova Therapeutics plc (MNK) Delisted | Tax (F) | −458 | -$25.5K | EDGAR |
| 2016-03-01 | Asterias Biotherapeutics, Inc. (AST) Delisted | Grant (A) | — | $0 | EDGAR |
| 2015-05-14 | Keenova Therapeutics plc (MNK) Delisted | Mixed | — | -$4.91M | EDGAR |
| 2015-04-14 | Keenova Therapeutics plc (MNK) Delisted | Mixed | — | -$4.03M | EDGAR |
| 2015-03-23 | Keenova Therapeutics plc (MNK) Delisted | Mixed | +3,002 | -$79.5K | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.